5 Stocks With Poor Sales Growth — RNA EXAS GNCA NBIX ALDR

Advertisement

This week, these five stocks have the worst ratings in Sales Growth, one of the eight Fundamental Categories on Portfolio Grader.

RNA gets F’s in Earnings Momentum and Equity as well. For more information, get Portfolio Grader’s complete analysis of RNA stock.

Exact Sciences Corporation (EXAS) is a molecular diagnostics company, focuses on developing a molecular diagnostic technology for the early detection and prevention of colorectal pre-cancer and cancer. EXAS also gets an F in Equity. The price of EXAS is down 24.6% since the first of the year. This is worse than the Nasdaq, which has remained flat. For more information, get Portfolio Grader’s complete analysis of EXAS stock.

GNCA also gets F’s in Analyst Earnings Revisions, Equity and Cash Flow. For more information, get Portfolio Grader’s complete analysis of GNCA stock.

Neurocrine Biosciences, Inc. (NBIX) is focused on the discovery and development of therapeutics for neuropsychiatric, neuroinflammatory, and neurodegenerative diseases and disorders. NBIX also gets F’s in Analyst Earnings Revisions and Equity. For more information, get Portfolio Grader’s complete analysis of NBIX stock.

ALDR gets F’s in Earnings Momentum, Analyst Earnings Revisions and Earnings Surprises as well. For more information, get Portfolio Grader’s complete analysis of ALDR stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.


Article printed from InvestorPlace Media, https://investorplace.com/2015/09/5-stocks-with-poor-sales-growth-rna-exas-gnca-nbix-aldr-rna-exas-gnca/.

©2024 InvestorPlace Media, LLC